/
VRAX
$3.33+$0.15 (+4.82%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.5M
1M shares
52-week range
$2.50 – $28.50
3% from low
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-4546.74
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $99.9K | $123.8K | $0 | $8.6K | $156.4K | $6.3K |
| Cost of revenue | $54.1K | $133.3K | $0 | $9.9K | $105.8K | $59.4K |
| Gross profit | $45.7K | −$9.4K | $0 | −$1.4K | $50.6K | −$53.1K |
| Gross margin | 45.8% | -7.6% | — | -15.9% | 32.3% | -838.2% |
| R&D | $87.0K | $120.2K | $433.7K | $397.1K | $1.6M | $1.8M |
| Operating income | −$651.2K | −$644.5K | −$1.7M | −$5.7M | −$6.5M | −$6.2M |
| EBITDA | $2.5K | −$644.3K | −$750 | −$5.4M | −$6.6M | −$5.8M |
| Net income | −$801.1K | −$651.0K | −$1.7M | −$5.5M | −$6.7M | −$6.1M |
| Net margin | -802.1% | -525.8% | — | -63748.3% | -4304.8% | -95739.2% |
| EPS (diluted) | -17.50 | -14.25 | -37.50 | -128.25 | -84.00 | -48.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $4000 | $-6.00 | $-6.00–$-6.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$31.45
Price
$3.33
Implied upside
+845%
Peer comparison
Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
www.viraxbiolabs.com- Employees
- 19
- IPO / List date
- Jul 21, 2022
Held by traders on TradeandTell
No one on the platform currently holds VRAX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in VRAX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-26 | 1-for-25reverse |
| 2023-12-18 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded VRAX yet.
